Overview

CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1

Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, 24-week study to evaluate the efficacy and safety of AXS-02 in patients with CRPS-I.
Phase:
Phase 3
Details
Lead Sponsor:
Axsome Therapeutics, Inc.
Treatments:
Diphosphonates
Zoledronic Acid